Sponsor

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Clinical research sponsor

Published trials125
Recruiting shown6
Roles2
SourceClinicalTrials.gov

Clinical trials

60 shown
A Clinical Trial Evaluating TQF3250 Capsules in Patients With Type 2 Diabetes Mellitus and Overweight/ObesityNCT07747857 · lead sponsor · 2026-08-25
RECRUITING
Evaluation of the Inhaled TQC3721 Suspension in Patients With Moderate-to-Severe Chronic Obstructive Pulmonary DiseaseNCT07464587 · lead sponsor · 2026-04-14
RECRUITING
A Clinical Trial on the Efficacy and Safety of TQB6411 for InjectionNCT07367529 · lead sponsor · 2026-02-26
RECRUITING
D-1553 Tablet Versus Docetaxel Injection for KRAS G12C Mutation-positive Locally Advanced or Metastatic Non-small Cell Lung Cancer After Prior Standard Therapy FailureNCT06300177 · lead sponsor · 2024-03-28
RECRUITING
A Clinical Study of TQB2450 Injection Combined With Chemotherapy or Anlotinib Hydrochloride Capsule in the Treatment of Non Small Cell Lung CancerNCT05913089 · lead sponsor · 2023-06-14
RECRUITING
A Study of TQB2930 for Injection Monotherapy or Combination Therapy in Patients With Recurrent/Metastatic Breast CancerNCT06202261 · lead sponsor · 2023-04-13
RECRUITING
A Clinical Trial Comparing TQC3927 Inhaled Powder With Glycopyrronium Bromide and Formoterol Inhaled Aerosol (Biovoping® Lingchang®) for the Treatment of Chronic Obstructive Pulmonary DiseaseNCT07633314 · lead sponsor · 2026-12-01
SUSPENDED
A Clinical Trial of TQF3250 Capsules in Overweight/Obese Trial Participants With Poor Weight Control Through Simple Lifestyle InterventionNCT07798284 · lead sponsor · 2026-09-01
NOT_YET_RECRUITING
Clinical Trial of TQB3126 for Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy in Breast Cancer SubjectsNCT07697443 · lead sponsor · 2026-08-01
NOT_YET_RECRUITING
A Clinical Study to Evaluate the Pharmacokinetics and Safety of Anecatibin Fumarate Capsules in Subjects With Impaired Liver Function Versus Normal Liver FunctionNCT07538973 · lead sponsor · 2026-04-01
NOT_YET_RECRUITING
A Phase II Clinical Trial on the Efficacy and Safety of TQC3721 Inhalation PowderNCT07252908 · lead sponsor · 2025-12-22
COMPLETED
Clinical Trial to Evaluate the Tolerance of TQB3201 TabletsNCT07172126 · lead sponsor · 2025-09-01
NOT_YET_RECRUITING
Evaluation of the Clinical Trial of Inhaled TQC3721 Suspension in Patients With Moderate-to-Severe Chronic Obstructive Pulmonary DiseaseNCT07147946 · lead sponsor · 2025-09-01
NOT_YET_RECRUITING
Clinical Trial of Evaluating TQB3912 Tablets Combined With Fulvestrant Injection±TQB3616 Capsules for Locally Advanced or Metastatic Hormone Receptor(HR)-Positive and Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast CancerNCT06851442 · lead sponsor · 2025-05-16
TERMINATED
Carboplatin/Cisplatin + Etoposide + Benmelstobart Sequential Benmelstobart Combined With Anlotinib Versus Carboplatin/Cisplatin + Etoposide + Tislelizumab Sequential Tislelizumab in the Treatment of Extensive Stage Small Cell Lung CancerNCT06897579 · lead sponsor · 2025-04-07
TERMINATED
A Clinical Study Comparing Semaglutide Injection and Wegovy® for Weight Management in Obese SubjectsNCT06738979 · lead sponsor · 2025-03-20
COMPLETED
Evaluation of TQB3616 Capsules in a Phase II Clinical Trial for Recurrent/Metastatic Breast CancerNCT06702618 · lead sponsor · 2025-02-20
ACTIVE_NOT_RECRUITING
A Clinical Trial of TQC3927 Powder for Inhalation in Chronic Obstructive Pulmonary DiseaseNCT06711991 · lead sponsor · 2025-02-11
COMPLETED
A Clinical Study of TQC3721 Inhalation Powder in Patients With Chronic Obstructive Pulmonary DiseaseNCT06748079 · lead sponsor · 2024-12-03
COMPLETED
A Clinical Trial of TQB2102 for Injection in the Treatment of HER2 Low-Expressing Recurrent/Metastatic Breast CancerNCT06561607 · lead sponsor · 2024-10-11
ACTIVE_NOT_RECRUITING
A Clinical Trial of TQC3721 Suspension for Inhalation in Patients With Moderate to Severe Chronic Obstructive Pulmonary DiseaseNCT06527144 · lead sponsor · 2024-09-14
COMPLETED
A Clinical Study of TQB2450 Combined With Anlotinib in Limited-Stage Small Cell Lung Cancer PatientsNCT06469879 · lead sponsor · 2024-09-01
UNKNOWN
A Trial to Assess the Bioequivalence of Tiotropium Bromide Inhalation Powder in Healthy Adult Participants Under Fasting ConditionsNCT06487416 · lead sponsor · 2024-06-10
UNKNOWN
A Study of TQC3927 Powder for Inhalation in Healthy Adult SubjectsNCT06408285 · lead sponsor · 2024-05-22
COMPLETED
A Trial to Assess the Bioequivalence of Generic Tiotropium Bromide Inhalation Powder and Reference Product in Healthy Adult Participants Under Fasting Conditions (Pilot)NCT06326671 · lead sponsor · 2024-02-28
UNKNOWN
A Study of Neoadjuvant Treatment With TQB2102 for Injection for Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast CancerNCT06198751 · lead sponsor · 2024-02-05
ACTIVE_NOT_RECRUITING
Mass Balance Study of TQB3616NCT06149611 · lead sponsor · 2024-01-01
UNKNOWN
A Clinical Study of TQH3821 Tablets in the Treatment of Treated Rheumatoid ArthritisNCT05849727 · lead sponsor · 2023-08-30
TERMINATED
A Clinical Trial of TQC3721 Suspension for Inhalation in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease.NCT05987371 · lead sponsor · 2023-08-23
COMPLETED
Evaluation of the Efficacy and Safety of AL2846 Capsule Combined With TQB2450 Injection Compared to Docetaxel Injection in Advanced Non-small Cell Lung Cancer Patients Who Have Failed With Immunotherapy.NCT05922345 · lead sponsor · 2023-06-08
UNKNOWN
To Evaluate the Efficacy and Safety of TQB3728 Tablets in Sequential Maintenance of TQB2450 Injection Therapy in Patients After Sequential or Concurrent Chemoradiation for Locally Advanced Non-small Cell Lung Cancer.NCT05859373 · lead sponsor · 2023-06-01
UNKNOWN
Clinical Study on Adjuvant Therapy of TQB3616 Combined With Endocrine Therapy Compared With Placebo Combined With Endocrine Therapy in Patients With Breast CancerNCT05780567 · lead sponsor · 2023-03-30
ACTIVE_NOT_RECRUITING
A Clinical Trial of TQB3909 Tablets in Patients With Breast CancerNCT05775575 · lead sponsor · 2023-03-02
UNKNOWN
Clinical Study of AL2846 Capsules in the Treatment of Advanced Lung Tumor and Advanced Ovarian CancerNCT05815862 · lead sponsor · 2023-02-15
COMPLETED
TQB2450 Injection Combined With Chemotherapy Followed by Sequential Combination With Anlotinib Hydrochloride Capsule for First-line Treatment of Advanced Squamous Non-small Cell Lung Cancer.NCT05718167 · lead sponsor · 2023-02-01
UNKNOWN
A Study to Evaluate the Sensitivity and Specificity of Inhaled Methacholine in Bronchial Provocation TestNCT05634473 · lead sponsor · 2022-12-01
UNKNOWN
Evaluate the Efficacy and Safety of TQC2731 Injection in Patients With Severe Asthma.NCT05472324 · lead sponsor · 2022-09-23
COMPLETED
To Evaluate the Efficacy of TQB3823 Combined With Abiraterone and Prednisone in Metastatic Castration-resistant Prostate Cancer Patientsprednisone Acetate Tablets in Patients With Metastatic Castration-resistant Prostate CancerNCT05405439 · lead sponsor · 2022-08-25
TERMINATED
To Evaluate the Efficacy and Safety of TQB3616 in Combination With Fulvestrant Versus Placebo in Combination With Fulvestrant in Previously Untreated Hormone-receptor (HR)-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Advanced Breast CancerNCT05365178 · lead sponsor · 2022-07-01
ACTIVE_NOT_RECRUITING
A Clinical Trial of Safety and Tolerance of TQH3821 Tablets in Adult Healthy SubjectsNCT05380934 · lead sponsor · 2022-05-29
COMPLETED
A Phase II Clinical Trial of TQC3721 Suspension for InhalationNCT05292196 · lead sponsor · 2022-05-20
TERMINATED
TQB3616 Capsules Plus Fulvestrant Compared to Placebo Plus Fulvestrant in Previously Treated Breast Cancer in Clinical TrailNCT05375461 · lead sponsor · 2022-03-18
COMPLETED
TQ-B3525 Tablets Combined With Osimertinib Mesylate Tablets in the Treatment of Advanced Non-Small Cell Lung CancerNCT05284994 · lead sponsor · 2022-03-11
UNKNOWN
A Study of TQB2450 Injection Plus Chemotherapy Followed by TQB2450 Plus Anlotinib Versus Tislelizumab Plus Chemotherapy Followed by Tislelizumab in the Treatment of First-line Non-squamous Non-small Cell Lung Cancer(NSCLC).NCT05346952 · lead sponsor · 2022-01-25
UNKNOWN
Cardiovascular Contrast-enhanced Magnetic Resonance Imaging Using Polysaccharide Superparamagnetic Iron Oxide Injection in Diabetic PatientsNCT06051565 · lead sponsor · 2021-11-06
COMPLETED
A Clinical Trial of TQC3721 Suspension for InhalationNCT05051930 · lead sponsor · 2021-10-18
UNKNOWN
A Clinical Study of TQB3616 Capsules Combined With Anlotinib Hydrochloride Capsules or Standard Chemotherapy Second-line and Above in the Treatment of Advanced Lung CancerNCT04924192 · lead sponsor · 2021-08-18
TERMINATED
A Clinical Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsules Versus K Drug in the Treatment of First-line Non-small Cell Lung Cancer(NSCLC)NCT04964479 · lead sponsor · 2021-08-06
UNKNOWN
A Clinical Study of Insulin Degludec Injection in Subjects With Type 2 DiabetesNCT04955834 · lead sponsor · 2021-07-27
UNKNOWN
Clinical Trial for Effect of TQB3616 Capsule on Pharmacokinetics in Healthy Adult SubjectsNCT05344729 · lead sponsor · 2021-07-06
COMPLETED
Phase I Clinical Trial of TQC2731 InjectionNCT04923607 · lead sponsor · 2021-06-25
UNKNOWN
A Study to Evaluate the Tolerance and Pharmacokinetics of TQB3720 TabletsNCT04853498 · lead sponsor · 2021-06-09
TERMINATED
A Study of TQB3616 Capsules Combined With Fulvestrant Injection in Subjects With Advanced Breast CancerNCT04796623 · lead sponsor · 2021-02-04
COMPLETED
Clinical Study to Evaluate the Efficacy and Safety of TQB2440 Injection/Perjeta® Combined With Trastuzumab and Docetaxel in the Treatment of Patients With Early or Locally Advanced Breast Cancer.NCT05985187 · lead sponsor · 2020-10-20
UNKNOWN
A Study of AL2846 Versus Zoledronic Acid in Subjects With Advanced Non-Small Cell Lung Cancer With Bone MetastasisNCT04325776 · lead sponsor · 2020-09-24
UNKNOWN
A Phase I Study of TQ-B3456 on Tolerance and PharmacokineticsNCT03754244 · lead sponsor · 2020-09-24
TERMINATED
A Study of TQ-B3139 Capsules in Subjects With MET-Altered Advanced Non-small Cell Lung CancerNCT04398940 · lead sponsor · 2020-08-11
UNKNOWN
A Clinical Study to Evaluate the Tolerance, Pharmacokinetics and Efficacy of TQ-A3334 TabletsNCT06507891 · lead sponsor · 2020-07-06
TERMINATED
A Study to Evaluate the Tolerance, Pharmacokinetics and Efficacy of TQ-A3334 TabletsNCT04273815 · lead sponsor · 2020-07-06
UNKNOWN
A Study of TQ-B3525 Tablets Combined With Fulvestrant Injection in Subjects With HR-positive, HER2-negative and PIK3CA Mutation Advanced Breast CancerNCT04355520 · lead sponsor · 2020-07-01
UNKNOWN

Sponsor roles

lead sponsor90
collaborator35

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.